Cargando…
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Tumor relapse and metastasis are the primary causes of poor survival rates in patients with advanced cancer despite successful resection or chemotherapeutic treatment. A primary cause of relapse and metastasis is the persistence of cancer stem cells (CSCs), which are highly resistant to chemotherapy...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484413/ https://www.ncbi.nlm.nih.gov/pubmed/25986923 |
_version_ | 1782378658522988544 |
---|---|
author | Mitra, Abhisek Mishra, Lopa Li, Shulin |
author_facet | Mitra, Abhisek Mishra, Lopa Li, Shulin |
author_sort | Mitra, Abhisek |
collection | PubMed |
description | Tumor relapse and metastasis are the primary causes of poor survival rates in patients with advanced cancer despite successful resection or chemotherapeutic treatment. A primary cause of relapse and metastasis is the persistence of cancer stem cells (CSCs), which are highly resistant to chemotherapy. Although highly efficacious drugs suppressing several subpopulations of CSCs in various tissue-specific cancers are available, recurrence is still common in patients. To find more suitable therapy for relapse, the mechanisms underlying metastasis and drug-resistance associated with relapse-initiating CSCs need to be identified. Recent studies in circulating tumor cells (CTCs) of some cancer patients manifest phenotypes of both CSCs and epithelial-mesenchymal transition (EMT). These patients are unresponsive to standard chemotherapies and have low progression free survival, suggesting that EMT-positive CTCs are related to co-occur with or transform into relapse-initiating CSCs. Furthermore, EMT programming in cancer cells enables in the remodeling of extracellular matrix to break the dormancy of relapse-initiating CSCs. In this review, we extensively discuss the association of the EMT program with CTCs and CSCs to characterize a subpopulation of patients prone to relapses. Identifying the mechanisms by which EMT-transformed CTCs and CSCs initiate relapse could facilitate the development of new or enhanced personalized therapeutic regimens. |
format | Online Article Text |
id | pubmed-4484413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-44844132015-07-10 EMT, CTCs and CSCs in tumor relapse and drug-resistance Mitra, Abhisek Mishra, Lopa Li, Shulin Oncotarget Review Tumor relapse and metastasis are the primary causes of poor survival rates in patients with advanced cancer despite successful resection or chemotherapeutic treatment. A primary cause of relapse and metastasis is the persistence of cancer stem cells (CSCs), which are highly resistant to chemotherapy. Although highly efficacious drugs suppressing several subpopulations of CSCs in various tissue-specific cancers are available, recurrence is still common in patients. To find more suitable therapy for relapse, the mechanisms underlying metastasis and drug-resistance associated with relapse-initiating CSCs need to be identified. Recent studies in circulating tumor cells (CTCs) of some cancer patients manifest phenotypes of both CSCs and epithelial-mesenchymal transition (EMT). These patients are unresponsive to standard chemotherapies and have low progression free survival, suggesting that EMT-positive CTCs are related to co-occur with or transform into relapse-initiating CSCs. Furthermore, EMT programming in cancer cells enables in the remodeling of extracellular matrix to break the dormancy of relapse-initiating CSCs. In this review, we extensively discuss the association of the EMT program with CTCs and CSCs to characterize a subpopulation of patients prone to relapses. Identifying the mechanisms by which EMT-transformed CTCs and CSCs initiate relapse could facilitate the development of new or enhanced personalized therapeutic regimens. Impact Journals LLC 2015-05-08 /pmc/articles/PMC4484413/ /pubmed/25986923 Text en Copyright: © 2015 Mitra et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Mitra, Abhisek Mishra, Lopa Li, Shulin EMT, CTCs and CSCs in tumor relapse and drug-resistance |
title | EMT, CTCs and CSCs in tumor relapse and drug-resistance |
title_full | EMT, CTCs and CSCs in tumor relapse and drug-resistance |
title_fullStr | EMT, CTCs and CSCs in tumor relapse and drug-resistance |
title_full_unstemmed | EMT, CTCs and CSCs in tumor relapse and drug-resistance |
title_short | EMT, CTCs and CSCs in tumor relapse and drug-resistance |
title_sort | emt, ctcs and cscs in tumor relapse and drug-resistance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484413/ https://www.ncbi.nlm.nih.gov/pubmed/25986923 |
work_keys_str_mv | AT mitraabhisek emtctcsandcscsintumorrelapseanddrugresistance AT mishralopa emtctcsandcscsintumorrelapseanddrugresistance AT lishulin emtctcsandcscsintumorrelapseanddrugresistance |